Security
United Health Products, Inc. Common Stock · UEEC
UEECOTCCommon stockCurrentCIK 1096938Updated Oct 6, 2026
Name history
United EcoEnergy Corp. · through Aug 17, 2010MNS EAGLE EQUITY GROUP III INC · through Jan 19, 2006
UEEC price & chart
Loading TradingView…
OTC:UEEC on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
424B3 filing
10-Q filing
Other Events
Items 8.01, 9.01
424B3 filing
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 94,313Source | 150,629Source | 247,985Source | 81,538Source | 121,688Source | 248,825Source | 104,542Source | 233,320Source | 316,698Source | 269,979Source | 284,643Source | 350,528Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | — | — | — | — | — | — | — | 13,377Source |
| Inventory, NetUSD | — | 0Source | — | — | 0Source | — | — | 33,598Source | — | 0Source | 33,598Source | 34,730Source |
| Assets, CurrentUSD | 43,129Source | 63,691Source | 64,664Source | 21,111Source | 26,294Source | 47,200Source | 35,082Source | 129,652Source | 105,392Source | 191,683Source | 151,822Source | 71,039Source |
| Prepaid Expense and Other Assets, CurrentUSD | 24,753Source | 19,908Source | 40,169Source | 20,886Source | 7,540Source | 46,171Source | 30,168Source | 15,172Source | 40,143Source | 22,800Source | 22,804Source | 22,932Source |
| Operating Lease, Right-of-Use AssetUSD | 23,021Source | 54,726Source | 0Source | 31,252Source | 62,169Source | 5,906Source | 39,273Source | 69,430Source | 14,574Source | 47,096Source | 76,520Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,433,856Source | 2,261,886Source | 4,690,801Source | 3,252,090Source | 2,124,109Source | 4,441,118Source | 2,959,907Source | 2,029,310Source | 4,193,149Source | 2,713,810Source | 1,998,869Source | 2,415,455Source |
| Commitments and ContingenciesUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 0Source | — | 0Source |
| Common Stock, Value, IssuedUSD | 258,690Source | 249,633Source | 261,585Source | 257,333Source | 248,233Source | 258,690Source | 257,133Source | 246,833Source | 258,690Source | 252,408Source | 244,783Source | 230,871Source |
| Additional Paid in CapitalUSD | 77,235,150Source | 75,525,941Source | 77,374,393Source | 77,136,474Source | 75,332,515Source | 77,235,150Source | 77,120,104Source | 75,108,325Source | 77,235,150Source | 76,004,704Source | 74,740,201Source | 71,830,695Source |
| Retained Earnings (Accumulated Deficit)USD | -80,833,383Source | -77,886,831Source | -82,078,794Source | -80,547,789Source | -77,583,169Source | -81,686,133Source | -80,232,602Source | -77,151,148Source | -81,370,291Source | -78,700,943Source | -76,699,210Source | -74,075,943Source |
| Stockholders' Equity Attributable to ParentUSD | -3,339,543Source | -2,111,257Source | -4,442,816Source | -3,192,937Source | -2,002,421Source | -4,192,293Source | -2,855,365Source | -1,795,990Source | -3,876,451Source | -2,443,831Source | -1,714,226Source | -2,064,927Source |
| Liabilities and EquityUSD | 94,313Source | 150,629Source | 247,985Source | 81,538Source | 121,688Source | 248,825Source | 104,542Source | 233,320Source | 316,698Source | 269,979Source | 284,643Source | 350,528Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,006,356Source | 2,235,411Source | 4,188,234Source | 1,904,590Source | 2,090,832Source | 4,191,118Source | 1,806,268Source | 1,989,004Source | 3,943,149Source | 1,641,152Source | 1,950,380Source | 2,415,455Source |
| Operating Lease, Liability, CurrentUSD | 23,954Source | 29,640Source | 0Source | 32,535Source | 30,277Source | 6,139Source | 34,531Source | 30,277Source | 15,157Source | 33,331Source | 28,838Source | — |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 26,475Source | 0Source | 0Source | 33,277Source | 0Source | 6,139Source | 40,306Source | 0Source | 15,158Source | 48,489Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | 325,437Source | — | — | 275,956Source | — | — | 226,475Source | — |
| Long-term Debt | —Source | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 1,687,501Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 483,450Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | 0Source | — | 1,132Source | 34,730Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -84,339Source | -273,969Source | -1,186,942Source | -1,194,716Source | -2,200,645Source | -619,720Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | -2,850Source | -40,500Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 50,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 20,119Source | 110,000Source | 1,083,308Source | 1,268,179Source | 2,285,538Source | 651,798Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 10,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 18,376Source | 43,783Source | 24,495Source | 225Source | 1,029Source | 4,914Source | 65,249Source | 168,883Source | 95,420Source | 13,377Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 703Source | 12,871Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Sale of DerivativesUSD | — | — | — | — | -33,898Source | 0Source | 22,404Source | 0Source | 28,334Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 115,085Source | — | — | — | — | 0Source | 115,085Source | 80,532Source | -209,598Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 0Source | 33,598Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -285,594Source | -303,662Source | -284,140Source | -315,187Source | -315,842Source | -1,531,659Source | -2,669,348Source | -2,001,733Source | -2,623,267Source | -1,687,501Source |
| Operating ExpensesUSD | — | — | 233,179Source | 391,903Source | 166,850Source | 268,356Source | 265,581Source | 1,489,216Source | 2,255,474Source | 2,007,572Source | 2,426,539Source | 2,820,895Source |
| Other Nonoperating Income (Expense)USD | — | — | -52,415Source | 88,241Source | -117,290Source | -46,831Source | -50,261Source | -42,443Source | -413,874Source | 5,839Source | -196,728Source | 1,114,538Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 2,326,074Source | 175,887Source |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 37,500Source |
| Cost of RevenueUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 18,644Source |
| Selling, General and Administrative ExpenseUSD | — | — | 207,845Source | 326,018Source | 162,998Source | 187,373Source | 253,019Source | 1,372,965Source | 1,985,607Source | 1,651,636Source | 1,827,729Source | 2,196,331Source |
| Operating Income (Loss)USD | — | — | -233,179Source | -391,903Source | -166,850Source | -268,356Source | -265,581Source | -1,489,216Source | -2,255,474Source | -2,007,572Source | -2,426,539Source | -2,802,039Source |
| Other Nonoperating Income (Expense)USD | — | — | -52,415Source | 88,241Source | -117,290Source | -46,831Source | -50,261Source | -42,443Source | -413,874Source | 5,839Source | -196,728Source | 1,114,538Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -285,594Source | -303,662Source | -284,140Source | -315,187Source | -315,842Source | -1,531,659Source | -2,669,348Source | -2,001,733Source | -2,623,267Source | -1,687,501Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | -0.01Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 257,809,759Source | 248,614,744Source | 260,040,591Source | 257,139,815Source | 258,690,253Source | 254,577,389Source | 256,981,335Source | 248,173,249Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 1,013Source | 1,013Source | 4,050Source | 4,050Source | 4,050Source | — |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 18,856Source |
| Interest ExpenseUSD | — | — | 30,684Source | 7,613Source | 50,456Source | 25,100Source | — | — | — | — | 40,512Source | 17,022Source |
| Interest Expense, DebtUSD | — | — | 30,684Source | 7,613Source | 48,212Source | 25,100Source | 48,109Source | 20,712Source | 113,284Source | 32,322Source | 32,875Source | — |
| Marketing and Advertising ExpenseUSD | — | — | — | — | — | — | 26,400Source | 27,208Source | 123,024Source | 111,824Source | 111,104Source | 112,036Source |
| Operating ExpensesUSD | — | — | 233,179Source | 391,903Source | 166,850Source | 268,356Source | 265,581Source | 1,489,216Source | 2,255,474Source | 2,007,572Source | 2,426,539Source | 2,820,895Source |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | 8,896Source | 8,554Source | 36,382Source | 35,584Source | 20,757Source | — |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 1,402,981Source |
| Research and Development ExpenseUSD | — | — | 25,334Source | 65,885Source | 3,852Source | 80,983Source | 12,562Source | 116,251Source | 269,867Source | 355,936Source | 598,810Source | 624,564Source |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-292761
Filing attachments
ueec_ex991.htm · 8-K · 2026-07-10
EX-99.1 2 ueec_ex991.htm PRESS RELEASE ueec_ex991.htm EXHIBIT 99.1 United Health Products Establishes Collaboration to Conduct Clinical Study DARIEN, CT - July 7, 2026 - United Health Products, Inc. (OTCQB: UEEC) today announced an agreement with NAMSA, a global leader in MedTech contract research, whereby NAMSA will serve as Sponsor of a new clinical study of UHP's CelluSTAT Hemostatic Gauze. Consistent with the company's recent proposal to the FDA to have a non-affiliated party oversee…
Read attachment ↗ueec_ex107.htm · S-1 · 2026-01-15
EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) United Health Products, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Fee Calculation Amount to be Proposed Maximum Proposed Fee Rate Amount of Title Rule …
Read attachment ↗ueec_ex41.htm · 8-K · 2025-12-22
EX-4.1 2 ueec_ex41.htm CONVERTIBLE PROMISSORY NOTE ueec_ex41.htm EXHIBIT 4.1 CERTAIN INFORMATION, IDENTIFIED BY [***], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL, AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONVERTIBLE PROMISSORY NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMEND…
Read attachment ↗ueec_ex42.htm · 8-K · 2025-12-22
EX-4.2 3 ueec_ex42.htm FORM OF COMMON STOCK PURCHASE WARRANT ueec_ex42.htm EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY OTHER JURISDICTIONS. AS A RESULT, THESE SECURITIES MAY NOT BE OFFERED, TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS (PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM …
Read attachment ↗ueec_ex991.htm · 8-K · 2025-05-08
EX-99.1 2 ueec_ex991.htm PRESS RELEASE ueec_ex991.htm EXHIBIT 99.1 United Health Products Announces OTCQB Uplisting and FDA Update Mount Laurel, New Jersey - May 1, 2025 - United Health Products, Inc. (OTCQB: UEEC) is pleased to announce that it has been approved to have its common shares uplisted from the OTC “Pink” market to the OTCQB Venture Market (“OTCQB”). The successful uplisting is effective May 1, 2025 and the company’s common shares will continue to trade under the ticker symbol…
Read attachment ↗